Ouro Fino Saúde Animal Participações (OFSA3) Q3 2025 earnings summary

Executive summary

• Net revenue grew 26.2% year-over-year to R$356.5 million in 3Q25 and 18.7% to R$805.3 million for the nine-month period, driven by portfolio diversification, innovation, and new product launches.

• Adjusted EBITDA increased 30.6% to R$97.6 million in 3Q25 and 20.1% to R$166.0 million for 9M25.

• Recognized with the 2025 FINEP Innovation Award for the Southeast Region, highlighting commitment to R&D, innovation, and sustainability.

• Launched 8 new products in the last 12 months, including LeanVac, Safesui Glasser One, Nexlaner, and Wellpet, through internal development and partnerships.

• Completed the incorporation of Ouro Fino Agronegócio Ltda. on October 1, 2025, consolidating assets and operations.

Financial highlights

• Gross profit rose 22.1% year-over-year in 3Q25 to R$188.3 million; nine-month gross profit was R$413.5 million (+20.0%).

• Adjusted net income increased 29.3% to R$54.8 million in 3Q25; nine-month adjusted net income was R$80.7 million (+14.0%).

• Adjusted EBITDA margin reached 27.4% in 3Q25 (+1.0 p.p. YoY); nine-month margin at 20.6%.

• Cash and equivalents at period-end were R$206.6 million, with strong operating cash generation of R$32.5 million in 9M25.

• Dividend and capital returns to shareholders totaled R$155.1 million in 9M25, including a R$120 million capital reduction in January.

Outlook and guidance

• Strategic plan finalized for the next five years, targeting deeper penetration in South America and portfolio expansion.

• Continued focus on innovation, R&D investment, and expanding product portfolio and distribution channels, especially in Latin America.

• Strong liquidity position and access to credit lines support ongoing growth and shareholder returns.